Immunic AG | Finanzwire

Basculer en Français

9802	Companies
196573	Keywords
127561	Articles
104493	Press releases

Home
Companies
Immunic AG

BRIEF

published on 02/04/2026 at 12:35, 3 hours 20 minutes ago

Immunic Unveils Promising Phase 2 Trial Results for Vidofludimus Calcium

Vidofludimus Calcium Phase 2 Trial Progressive Multiple Sclerosis ACTRIMS Forum 2026 Antiviral Effects
PRESS RELEASE

published on 02/04/2026 at 12:30, 3 hours 25 minutes ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic to present additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, reinforcing potential in Progressive Multiple Sclerosis. Latest research findings to be shared at event

Immunic Vidofludimus Calcium Progressive Multiple Sclerosis Phase 2 CALLIPER Trial ACTRIMS Forum 2026
BRIEF

published on 01/07/2026 at 12:35, 28 days 3 hours ago

Immunic Reviews 2025 Progress and Sets Sights on Future Goals

Vidofludimus Calcium Neuroprotection Multiple Sclerosis Trials Immunic Accomplishments Biotechnology Milestones
PRESS RELEASE

published on 01/07/2026 at 12:30, 28 days 3 hours ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic Inc. highlights its 2025 accomplishments & upcoming milestones including phase 3 trials for Vidofludimus Calcium in relapsing Multiple Sclerosis, positive data in Progressive MS, & potential for IMU-856 in weight management

Immunic Inc. Multiple Sclerosis Vidofludimus Calcium IMU-856 2025 Accomplishments
BRIEF

published on 11/26/2025 at 12:35, 2 months 8 days ago

Immunic to Join Evercore ISI Healthcare Conference in December

Biotechnology Immunic Investor Meetings Healthcare Conference Neurologic Diseases
PRESS RELEASE

published on 11/26/2025 at 12:30, 2 months 8 days ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic to participate in the 8th Annual Evercore ISI Healthcare Conference in December. Dr. Daniel Vitt to speak at fireside chat on novel oral therapies for neurologic and gastrointestinal diseases

Gastrointestinal Diseases Immunic Neurologic Diseases Evercore ISI Healthcare Conference Daniel Vitt
BRIEF

published on 11/13/2025 at 12:35, 2 months 21 days ago

Immunic, Inc. Announces Third Quarter 2025 Financial Results and Updates

Financial Results Clinical Trials Immunic, Inc. Multiple Sclerosis Vidofludimus Calcium
PRESS RELEASE

published on 11/13/2025 at 12:30, 2 months 21 days ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2025 financial results and provides corporate update, highlighting vidofludimus calcium's therapeutic potential in multiple sclerosis. Phase 3 ENSURE trial data expected by 2026

Financial Results Immunic Inc. Vidofludimus Calcium Phase 3 Trials MS Therapy
BRIEF

published on 10/29/2025 at 11:35, 3 months 6 days ago

Immunic to Participate in Key November Conferences

Biotechnology Immunic Conference Participation BIO-Europe Jefferies Conference
PRESS RELEASE

published on 10/29/2025 at 11:30, 3 months 6 days ago

Immunic to Participate in Industry and Investor Conferences in November
Immunic, Inc. to participate in industry and investor conferences in November, presenting clinical pipeline of therapies for inflammatory diseases

Investor Conferences Immunic Inc. Clinical Pipeline Inflammatory Diseases Industry Conferences

1 2 ... 9

Accesswire

Published on 02/04/2026 at 15:45, 10 minutes ago

Patriot.Tv's Jd Rucker Explains Billie Eilish's Comments on ICE, Offers ICE Commentary as Exhibit A of Celebrity Sound Bite Politics
Published on 02/04/2026 at 15:00, 55 minutes ago

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale
Published on 02/04/2026 at 14:30, 1 hour 25 minutes ago

Datametrex Expands Business In Data Centres
Published on 02/04/2026 at 14:30, 1 hour 25 minutes ago

Core Silver Significantly Expands Copper-Molybdenum Footprint at Laverdiere Through Soil Sampling
Published on 02/04/2026 at 14:30, 1 hour 25 minutes ago

Klondike Gold Drills 600 Meter Step Out from Lone Star Deposit and Intersects Broad Interval of Gold Mineralization Extending Lone Star Target Zone to the Southwest

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 15:27, 28 minutes ago

EQS-Adhoc: LM Pay S.A.: Early Redemption of PLN 10M Bonds
Published on 02/04/2026 at 15:07, 48 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 02/04/2026 at 15:06, 49 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rio Tinto plc and Rio Tinto Limited
Published on 02/04/2026 at 15:05, 50 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Just Group plc
Published on 02/04/2026 at 15:05, 50 minutes ago

Artlist Debuts Its Big Game Ad Made In-House in Five Days Using AI

Les Echos

Published on 02/03/2026 at 17:45, 22 hours 10 minutes ago

Revenue growth in 2025 to €11.2m (+5%)
Published on 02/03/2026 at 08:00, 1 day 7 hours ago

EURAZEO & PANTHEON ESTABLISH A NEARLY €500 MILLION PRIVATE DEBT CONTINUATION VEHICLE
Published on 02/03/2026 at 08:00, 1 day 7 hours ago

Neoen launches three new solar farms in France with a total capacity of 230 MWp
Published on 02/02/2026 at 18:23, 1 day 21 hours ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:00, 1 day 21 hours ago

Covivio - Information on total number of voting rights and share capital

View all LES ECHOS COMFI WIRE